- PDF Free Download

33 6 2011 6 Journal of Ningxia Medical University 543 1674-6309 2011 06-0543 - 04 1 2 1 1 3 3 1. 750004 2. VIP 750004 3. 750004 70 20mg d - 1 6 1 3 C CRP B IMT Crouse 6 ADL 1 1 LDL - C CRP P < 0. 05 CRP P < 0. 05 P < 0. 05 3 TC LDL - C CRP P < 0. 01 3 1 TC LDL - C CRP P < 0. 05 3 CRP P > 0. 05 2 1 IMT P > 0. 05 3 1 IMT P < 0. 01 P > 0. 05 3 Crouse 1 P < 0. 05 3 6 ADL P < 0. 05 R743. 33 A 3 - - 3-1 A 1. 1 meta 2009 5-2010 3 70 1-2 80% 4 14d 80 3 3 CRP 1. 2 35 2011-01 - 20 97 E - mail yangpi123@163. com E - mail dyhmail2000@sina. com 20 mg d - 1 6 35 0. 1 g d - 1

544 33 TC TG HDL - C LDL - C 1. 5 SPSS 11. 5 CRP IMT 1 3 TC x 珋 ± s TG HDL - C P > LDL - C C CRP 0. 05 IMT P < 0. 05 1 3 Crouse LSD - ADL t χ 2 P < 0. 05 1. 3 HP Image Point 2 7. 5MHz B 2. 1 1. 0 70 47 23 35 2. 0 3. 0cm 3 IMT 22 13 59. 5 ± 11. 6 1. 0mm 35 25 10 61. 7 ± 12. 8 P > 0. 05 1 3 1 % 2 1. 5mm 35 35 P Crouse / 59. 5 ± 11. 6 61. 7 ± 12. 8 t = 0. 400 0. 690 22 62. 9 25 71. 4 χ 2 = 0. 587 0. 445 18 51. 4 21 60. 0 χ 2 = 0. 521 0. 471 8 22. 9 7 20. 0 χ 2 = 0. 085 0. 771 Crouse 12 34. 3 10 28. 6 χ 2 = 0. 265 0. 607 1. 4 21 60. 0 23 65. 7 χ 2 = 0. 245 0. 621 19 54. 3 21 60. 0 χ 2 = 0. 233 0. 629 5mL 3000 r min - 1 2. 2 CRP 2 10 min - 80 CRP 2 CRP x 珋 ± s 35 1 3 F 35 1 3 F TC / mmol L - 1 4. 41 ± 1. 16 4. 40 ± 1. 24 4. 22 ± 1. 05 *## 12. 315 4. 51 ± 1. 25 4. 47 ± 1. 07 4. 43 ± 0. 89 0. 174 TG / mmol L - 1 2. 00 ± 1. 47 1. 99 ± 1. 45 1. 96 ± 1. 43 1. 398 2. 02 ± 1. 01 2. 03 ± 0. 92 1. 99 ± 0. 87 0. 404 LDL - C / mmol L - 1 2. 60 ± 0. 92 2. 49 ± 0. 95 # 2. 17 ± 0. 88 **## 10. 716 2. 54 ± 0. 76 2. 51 ± 0. 72 2. 53 ± 0. 67 0. 327 HDL - C / mmol L - 1 0. 94 ± 0. 26 0. 94 ± 0. 25 0. 95 ± 0. 24 0. 216 0. 94 ± 0. 34 0. 93 ± 0. 25 0. 94 ± 0. 29 0. 312 CRP / mg L - 1 11. 2 ± 3. 1 6. 20 ± 2. 2 *## 2. 90 ± 1. 3 ## 22. 256 10. 9 ± 2. 8 7. 5 ± 2. 4 # 3. 2 ± 1. 8 ## 17. 359 * P < 0. 05 ** P < 0. 01 # P < 0. 05 ## P < 0. 01 1 P < 0. 05 P < 0. 01 2. 3 B 25 71. 4% 68 24 12 4 2 4 B 7 22 5 62 32 29 19 14 3 6 3 4 2

6. 545 2 3 P > 0. 05 3 IMT 1 3 Crouse P < 0. 05 P < 0. 01 3 4 3 IMT x 珋 ± s mm 1 3 F 35 1. 39 ± 0. 30 1. 37 ± 0. 26 1. 19 ± 0. 23 *# 29. 382 35 1. 34 ± 0. 27 1. 38 ± 0. 23 1. 38 ± 0. 22 0. 959 * P < 0. 01 # P < 0. 01 1 P < 0. 01 4 Crouse x 珋 ± s 25 1 3 F 22 1 3 F /cm 2 0. 92 ± 0. 14 0. 93 ± 0. 13 0. 89 ± 0. 14 1. 704 0. 94 ± 0. 10 0. 95 ± 0. 10 0. 96 ± 0. 12 0. 822 Crouse /cm 1. 10 ± 0. 39 1. 07 ± 0. 37 1. 01 ± 0. 37 *# 6. 412 1. 06 ± 0. 34 1. 10 ± 0. 35 1. 13 ± 0. 30 1. 584 * P < 0. 05 # P < 0. 05 1 P < 0. 05 2. 4 2 1 2. 5 24h CRP 2. 5 ADL 70 6 9 4 2 Kadikoylu G 10 8. 5% 6 ADL 20mg d - 1 14 TC 31 33 6 P < 0. 001 LDL - C P < 0. 001 ADL 85. 7 ± 8. 1 70. 5 ± 11. 9 3 SPARCL 1 LDL - C CRP 1 CRP 80 mg 1 3 TC 16% LDL - C CRP CRP 5 Sillese H 6 CRP CRP SPARCL TIA 1 IMT CAS 7 CRP P = 0. 003 P = 0. 001 TNF - a P < 0. 001 scd40 P < 0. 001 IL - 18 P = 0. 024 Kitamura A 11 1289 60 ~ 74 4. 5 IMT 3 8 IMT

546 33 IMT 4. J. 1996 29 6 379. 5 Amarenco P Boqousslavsky J Callahan A et al. High - PPAR_γ dose atorvastatin after stroke or transient ischemic attack γ 12 J. New Engl J Med 2006 355 6 549-559. MMPS 6 Sillesen H Amarenco P Hennerici MG et al. Atorvastatin reduces the risk of cardiovascular events in patients 13 14 40mg 80mg MRS NIHSS 80mg 3297-3302. 7 Huisa BN Stemer AB Zivin JA. Atorvastatin in stroke 15 3 a review of SPARCL and subgroup analysis J. Vasc Health Risk Manag 2010 6 4 229-236. 3 IMT 1 8 Paciaroni M Bogousslavsky J. Statins and stroke prevention J. Expert Rev Cardiovasc Ther 2009 7 10 1231-1243. 9 Idicula TT Brogger J Naess H et al. Admission C - reactive protein after acute ischemic stroke is associated Crouse 3 Crouse 1 with stroke severity and mortality The Bergen stroke study J. BMC Neurol 2009 9 1 18. 10 Kadikoylu G Uysal HB Yenisey C et al. The effects of atorvastatin on hematological and inflammatory parameters J. Blood 2008 112 11 1548. 11 Kitamura A Iso H Imano H et al. Carotid intima - media thickness and plaque characteristics as a risk factor for stroke in Japanese elderlymen J. Stroke 3 2004 35 12 2788-2794. 12 Clunn GF Sever PS Hughes AD. Calcium channel regulation in vascular smooth muscle cells Synergistic 3 ~ 6 effects of statins and calcium channel blockers J. Int LDL - C TC J Cardiol 2010 139 1 2-6. IMT 13 Luan Z Chase AJ Newby AC. Statins inhibit secretion HDL - C TG of metalloproteinases - 1-2 - 3 and - 9 from vascular smooth muscle cells and macrophages J. 3 ~ 6 Arte- 1 Csaszar A. Important aim of statin therapy ischemic cardiovascular event stroke 7-8 239-243. J. Ideggyogy Sz 2008 61 2 Welch KM. Review of the SPARCL trial and its subanalyses J. Curr Atheroscler Rep 2009 11 4 315-321. with carotid atherosclerosis J. Stroke 2008 39 12 rioscler Thromb Vasc Biol 2003 23 5 769-775. 14 Matsumura M Fukuda N Kobayashi N et al. effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats J. J Atheroscler Thromb 2009 16 4 319-326. 15 Lampl Y Lorberboym M Gilad R et al. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin J. Clin Neurophar - 3. macol 2010 33 3 129-134. J. 2010 31 8 925-928. 561

6. 561 limb group and 15 healthy volunteers were selected as normal control group. All subjects underwent Ultrasound US of the ulnar nerve. The findings of US measurement were compared with those of intra - operative and pre - operative electromyography. Results Detection of ulnar nerve compression with High - frequency ultrasound was high in both of limb group and control group. The thickness swelling rate of the ulnar nerve and the cross - sectional area CSA showed a significant difference between two groups P < 0. 05. The CSA and the ulnar nerve motor conduction velocity MNCV in group Limb showed significantly negative correlation r = - 0. 933 P < 0. 01. Conclusion High - frequency ultrasound is a painless non - invasive convenient way in dynamic real - time observation of signs of ulnar nerve compression. It has important reference value for diagnosis of cubital tunnel syndrome. Key words ulnar neuropathy cubital tunnel syndrome ultrasound entrapment neuropathy 546 Clinical Efficacy and Prognostic Value of Atorvastatin on Patients with Acute Cerebral Infarction YANG Ping 1 ZHANG Li - fang 2 GU Shu e 1 MA Da - wei 1 CHENG Jiang 3 DU Yan - hui 3 1. Ningxia Medical University Yinchuan 750004 2. Department of Neurology the General Hospital of Ningxia Medical University Yinchuan 750004 3. The Department of Neurophysiology the General Hospital of Ningxia Medical University Ningxia 750004 Abstract Objective To investigate the clinical efficacy and early prognostic value of atorvastatin in patients with acute cerebral infarction. Methods 70 patients with acute cerebral infarction were randomly divided into control group and atorvastatin group. The patients in the control group received conventional therapy while those in the atorvastatin group was administrated orally with 20mg of Atorvastatin. The indices of total cholesterol TC triglyceride TG lowerdensity lipoprotein - cholesterol LDL - C high density lipoprotein - cholesterol HDL - C C - reactive protein CRP carotid artery ultrasound and the carotid artery intima - media thickness IMT were compared respectively in the groups before and after treatment of the first month and the third month. Plaque area and plaque Crouse points were detected in patients with cerebral infarction. All patients were followed up for 6 months. Results 1 After 1 month treatment LDL - C and CRP levels in atorvastatin group significantly reduced compared with those before treatment P < 0. 01 and CRP also decreased in the control group P < 0. 05. After 3 months treatment in the atorvastatin group TC and LDL - C and CRP significantly reduced compared with those before treatment and after 1 month treatment P < 0. 05. 2 There was no significant difference on IMT between the two groups before treatment P > 0. 05 and after 1 month treatment the above was also no significant difference P > 0. 05. After 3 months treatment in the atorvastatin group the IMT significantly decreased P < 0. 01 Plaque area was no significant difference between the two groups P > 0. 05 Crouse score in the atorvastatin group were significantly lower than that in the control group P < 0. 05. 3 ADL score significantly increased in patients of atorvastatin group after six months treatment P < 0. 05. Conclusion Atorvastatin had early lipid - lowering and antiinflammatory effects on patients with acute cerebral infarction. It could stabilize or reverse the carotid artery plaque and improve the early prognosis. Key words acute cerebral infarction atorvastatin carotid artery ultrasound prognosis